Summit Therapeutics Inc
NASDAQ:SMMT
Summit Therapeutics Inc
NASDAQ:SMMT
Price:
16.58
USD
-3.94%
Market Closed
Market Cap:
$12.9B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Summit Therapeutics Inc
NASDAQ:SMMT
|
US |
|
D
|
DKSH Holdings (Malaysia) Bhd
KLSE:DKSH
|
MY |
|
Berkeley Group Holdings PLC
LSE:BKG
|
UK |
|
Midway Ltd
ASX:MWY
|
AU |
|
K
|
Kuehne und Nagel International AG
XBER:KNIA
|
CH |
|
D R Horton Inc
NYSE:DHI
|
US |
|
Z
|
Zhejiang Zhongxin Fluoride Materials Co Ltd
SZSE:002915
|
CN |
|
Chongqing Sanxia Paints Co Ltd
SZSE:000565
|
CN |
|
Atacadao SA
BOVESPA:CRFB3
|
BR |
|
N
|
Ningxia Zhongke Biotechnology Co Ltd
SSE:600165
|
CN |
|
Pharma Equity Group A/S
CSE:PEG
|
DK |
|
Y
|
Yamazawa Co Ltd
TSE:9993
|
JP |
|
Jiangsu Sainty Corp Ltd
SSE:600287
|
CN |
|
CanSino Biologics Inc
SSE:688185
|
CN |
|
E
|
Empresas CMPC SA
SGO:CMPC
|
CL |
|
Y
|
Y's Table Corp
TSE:2798
|
JP |
|
Hainan Yedao Group Co Ltd
SSE:600238
|
CN |
|
C
|
Circle Internet Group Inc
NYSE:CRCL
|
US |
|
M
|
Multi-Chem Ltd
SGX:AWZ
|
SG |
|
P
|
Powdertech Co Ltd
TSE:5695
|
JP |
Multiples-Based Value
The Multiples-Based Value of one
SMMT
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 16.58 USD,
Summit Therapeutics Inc
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
SMMT Multiples-Based Value
LOCKED
Multiples Across Competitors
SMMT Competitors Multiples
Summit Therapeutics Inc Competitors
Summit Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Summit Therapeutics Inc
NASDAQ:SMMT
|
12.9B USD | 0 | -17.2 | -16.5 | -16.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
370.2B USD | 6.1 | 88.4 | 14.7 | 20.4 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
355.4B USD | 109.4 | -1 708.3 | 15 870 | -1 791.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188B USD | 5.1 | 24.4 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
166.6B USD | 5.7 | 19.6 | 12.3 | 15.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110B USD | 9.2 | 27.8 | 20.9 | 21.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78B USD | 5.4 | 17.3 | 12.7 | 14.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69B AUD | 3.2 | 35.1 | 11.5 | 14.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
